Merck (MRK) EBITDA (2008 - 2026)
Merck (MRK) EBITDA from Jun 30, 2008 to Mar 31, 2026. The TTM Merck (MRK) EBITDA is $16B. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Quarterly EBITDA
Merck (MRK) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -30.82% |
| 3 Years TTM | -3.35% |
| 5 Years TTM | +10.17% |
| 10 Years TTM | +2.59% |
| All Time TTM | +7.45% |
Annual EBITDA change of Merck (MRK)
| Year | EBITDA | Change |
|---|---|---|
| 2026 | -$2.47B | -109.71% |
| 2025 | $25B | +9.29% |
| 2024 | $23B | +380.21% |
| 2023 | $4.85B | -74.76% |
| 2022 | $19B | +13.38% |
| 2021 | $17B | +55.44% |
| 2020 | $11B | -31.63% |
| 2019 | $16B | +13.80% |
| 2018 | $14B | +17.54% |
| 2017 | $12B | +10.41% |
| 2016 | $11B | -13.10% |
| 2015 | $12B | -49.66% |
| 2014 | $25B | +86.76% |
| 2013 | $13B | -18.89% |
| 2012 | $16B | +6.29% |
| 2011 | $15B | +59.29% |
| 2010 | $9.63B | -47.11% |
| 2009 | $18B | +55.73% |
| 2008 | $12B | +118.12% |
| 2007 | $5.36B | N/A |
Comparison Merck (MRK) five years EBITDA CAGR with competitors
Merck (MRK) five years EBITDA CAGR is 10.17%.
| Ticker | Name | five years EBITDA CAGR | Upside |
|---|---|---|---|
| LLY | Lilly(Eli) & Company | 30.95% | +204.49% |
| NVO | Novo Nordisk | 25.26% | +148.48% |
| AZN | Astrazeneca plc | 18.02% | +77.31% |
| GILD | Gilead Sciences Inc | 17.19% | +69.13% |
| BMY | Bristol-Myers Squibb Company | 13.61% | +33.86% |
| JNJ | Johnson & Johnson | 6.13% | -39.66% |
| NVS | Novartis AG | 5.31% | -47.72% |
| ABBV | Abbvie Inc | 4.99% | -50.89% |
| AMGN | AMGEN Inc | 4.42% | -56.54% |
| GRFS | Grifols SA | 2.72% | -73.20% |
| GSK | GSK Plc | 1.17% | -88.51% |